Search

Your search keyword '"Mota J."' showing total 1,106 results
Start Over Author "Mota J." Publication Type Academic Journals

Refine your results

more »

more »

more »

more »

more »
1,106 results on '"Mota J."'

3. Rethinking Schools as a Setting for Physical Activity Promotion in the 21st Century–a Position Paper of the Working Group of the 2PASS 4Health Project.

Author

García Bengoechea, E., Woods, C. B., Murtagh, E., Grady, C., Fabre, N., Lhuisset, L., Zunquin, G., Aibar, A., Zaragoza Casterad, J., Haerens, L., Verloigne, M., De Cocker, K., Hellebaut, S., Ribeiro, J., Bohn, L., Mota, J., and Bois, J. E.

Subjects
PHYSICAL activity, ADOLESCENT health, EXPERIMENTAL design, LEGAL evidence, EXPERTISE
Abstract

Schools are ideal settings to promote adolescent physical activity (PA), yet school-based interventions have shown limited long-term impact. This position paper presents key issues surrounding school-based PA interventions. Collaborative conceptual thinking drawing on multi-author expertise and available evidence advanced our understanding and opinion. Key arguments: 1) the adoption of a systems approach, which maximizes partnership action and leverages policy, is crucial for understanding the complexities of implementing whole-school programs; 2) a reorientation to an assets perspective optimizes existing strengths and resources allowing greater emphasis on the full range of physical, cognitive, emotional and social benefits that PA provides, and 3) a move beyond traditional positivist research designs to advance our knowledge of what works better, for whom and in what context is needed for greater progress We provide suggestions, specifically advocating for systems approaches, as a realistic way to improve how we support PA in schools in the future. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Creating access to SARS-CoV-2 screening and testing through community-based COVID-19 case-finding, observations from cross-sectional studies in Lesotho and Zambia

Author

Eveline Klinkenberg, Bulemba Katende, Maria Ruperez, Moniek Bresser, Bxyn Kangololo, Justin Bwalya, Rahel M. Erhardt, Ab Schaap, Nkatya Kasese, Thomas Gatchie, Sian Floyd, ‘Mota J. ‘Mota, Helen Ayles, Kwame Shanaube, and Klaus Reither

Subjects
COVID-19, Community testing, Lesotho, Zambia, SARS-CoV-2, Public aspects of medicine, RA1-1270
Abstract

Abstract Background The health impact of the COVID-19 pandemic largely depends on the ability of the healthcare systems to develop effective and adaptable preparedness and mitigation strategies. A collaborative initiative (BRCCH-EDCTP COVID-19 Initiative) was set up between Lesotho and Zambia early on in the pandemic, to jointly conduct a project to investigate creating access to SARS-CoV-2 screening and testing through community-based COVID-19 case-finding. Methods Two different community case-finding strategies were deployed. In Lesotho, an approach was implemented whereby a community (village) health worker screened community members at their home or during community gatherings for COVID-19 signs and symptoms. All community members who screened positive were then offered SARS-CoV-2 testing. In Zambia, so-called community hubs, staffed by community health care workers, were set up at different locations in the community for people to walk in and get tested for SARS-CoV-2. Hubs changed location from week-to-week and targeted transmission hotspots. All persons visiting the hubs were offered testing for SARS-CoV-2 irrespective of self-reported signs and symptoms of COVID-19 though information was collected on occurrence of these. Testing in both approaches was done using SARS-CoV-2 rapid antigen tests. Results Setting up testing in the community setting was feasible in both countries. In Lesotho in the village health worker approach, over a period of 46 weeks, 7221 persons were screened, and 49 (11.4%) SARS-COV-2 cases identified among 428 COVID-19 screen positive participants. In the community hubs among 3150 people tested, 166 (5.3%) SARS-CoV-2 cases were identified in a period of 26 weeks. From the community hubs approach, where all seen were offered COVID-19 testing it was learned that people screening positive for COVID-19 signs and symptoms were more likely to test SARS-COV-2 positive, especially those reporting classic COVID-19 symptoms like loss of sense/smell for a short period of time (1–3 days). Conclusions In conclusion, in this project we learned that implementing COVID-19 screening and testing by lay health workers in the community is possible. Characteristics of the population screened, tested, and identified to have SARS-CoV-2 are described to help guide development of future testing strategies.

Published
2023
Full Text
View/download PDF

6. Evaluation of recorded video-observed therapy for anti-tuberculosis treatment

Author

Garfein, RS, Liu, L, Cuevas-Mota, J, Collins, K, Catanzaro, DG, Muñoz, F, Moser, K, Chuck, C, Higashi, J, Bulterys, MA, Raab, F, and Rios, P

Subjects
Infectious Diseases, Tuberculosis, Clinical Research, Rare Diseases, Vaccine Related, Infection, Good Health and Well Being, Adolescent, Adult, Aged, Aged, 80 and over, Antitubercular Agents, Directly Observed Therapy, Female, Humans, Male, Middle Aged, New York City, San Francisco, United States, Young Adult, mHealth, monitoring, adherence, Cardiorespiratory Medicine and Haematology, Microbiology
Abstract

BACKGROUND: Asynchronous video directly observed therapy (VDOT) may reduce tuberculosis (TB) program costs and the burden on patients. We compared VDOT performance across three cities in the United States, each of which have TB incidence rates above the national average.METHODS: Patients aged ≥18 years who are currently receiving directly observed anti-TB treatment were invited to use VDOT for monitoring treatment. Pre- and post-treatment interviews and medical records were used to assess site differences in treatment adherence and patient characteristics and perceptions.RESULTS: Participants were enrolled in New York City, NY (n = 48), San Diego, CA (n = 52) and San Francisco, CA, USA (n = 49). Overall, the mean age was 41 years (range 18-87); 59% were male; most were Asian (45%) or Hispanic/Latino (30%); and 77% were foreign-born. The median fraction of expected doses observed (FEDO) was 88% (IQR 76-96). At follow-up, 97% thought VDOT was "very or somewhat easy to use" and 95% would recommend VDOT to other TB patients. Age, race/ethnicity, annual income, and country of birth differed by city (P < 0.05), but FEDO and VDOT perceptions did not.CONCLUSIONS: TB programs in three large US cities observed a high FEDO using VDOT while minimizing staff time and travel. Similar findings across sites support VDOT adoption by other large, urban TB programs.

Published
2020

9. Mycobacterium tuberculosis infection among persons who inject drugs in San Diego, California

Author

Armenta, RF, Collins, KM, Strathdee, SA, Bulterys, MA, Munoz, F, Cuevas-Mota, J, Chiles, P, and Garfein, RS

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Liver Disease, Drug Abuse (NIDA only), Infectious Diseases, Clinical Research, Digestive Diseases, Rare Diseases, Sexually Transmitted Infections, HIV/AIDS, Substance Misuse, Emerging Infectious Diseases, Tuberculosis, Hepatitis - C, Hepatitis, 6.1 Pharmaceuticals, Infection, Good Health and Well Being, Adolescent, Adult, Aged, Aged, 80 and over, California, Coinfection, Cross-Sectional Studies, Female, HIV Infections, Hepatitis C, Humans, Interferon-gamma Release Tests, Latent Tuberculosis, Male, Middle Aged, Point-of-Care Systems, Prevalence, Risk Factors, Substance Abuse, Intravenous, Travel, Young Adult, injection drug use, HIV, QuantiFERON((R))-TB Gold In-Tube assay, latent tuberculous infection, PWID, Cardiorespiratory Medicine and Haematology, Microbiology, Cardiovascular medicine and haematology, Clinical sciences, Epidemiology
Abstract

BackgroundPersons who inject drugs (PWID) might be at increased risk for Mycobacterium tuberculosis infection and reactivation of latent tuberculous infection (LTBI) due to their injection drug use.ObjectivesTo determine prevalence and correlates of M. tuberculosis infection among PWID in San Diego, California, USA.MethodsPWID aged 18 years underwent standardized interviews and serologic testing using an interferon-gamma release assay (IGRA) for LTBI and rapid point-of-care assays for human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections. Independent correlates of M. tuberculosis infection were identified using multivariable log-binomial regression.ResultsA total of 500 participants met the eligibility criteria. The mean age was 43.2 years (standard deviation 11.6); most subjects were White (52%) or Hispanic (30.8%), and male (75%). Overall, 86.7% reported having ever traveled to Mexico. Prevalence of M. tuberculosis infection was 23.6%; 0.8% were co-infected with HIV and 81.7% were co-infected with HCV. Almost all participants (95%) had been previously tested for M. tuberculosis; 7.6% had been previously told they were infected. M. tuberculosis infection was independently associated with being Hispanic, having longer injection histories, testing HCV-positive, and correctly reporting that people with 'sleeping' TB cannot infect others.ConclusionsStrategies are needed to increase awareness about and treatment for M. tuberculosis infection among PWID in the US/Mexico border region.

Published
2017

15. Prevalence and Correlates of the Use of Prefilled Syringes Among Persons Who Inject Drugs in San Diego, CA

Author

Armenta, RF, Roth, AM, Wagner, KD, Strathdee, SA, Brodine, SK, Cuevas-Mota, J, Munoz, FA, and Garfein, RS

Subjects
Injection drug use, HIV, Hepatitis C, Prefilled syringes, Overdose, Prevention, Clinical Research, Substance Abuse, Digestive Diseases, Drug Abuse (NIDA Only), Public Health, Human Movement and Sports Sciences, Public Health and Health Services
Abstract

© 2015 The New York Academy of Medicine Persons who inject drugs (PWID) are at increased risk for blood-borne virus (BBV) infections and overdose resulting from high-risk injecting practices. Studies of prefilled syringe use ([PFSU] using a syringe that already contained drug solution when it was obtained by the user), an injection practice previously described in Eastern Europe, suggest that it increases susceptibility to BBV. However, little is known about this practice in the USA. Data were obtained from an ongoing cohort study of PWID to determine the prevalence and assess correlates of PFSU in San Diego, CA. Baseline interviews assessed socio-demographics and drug use behaviors. Logistic regression was used to identify factors independently associated with ever using a prefilled syringe (yes/no). Participants (n = 574) were predominately males (73.9 %) and white (50.9 %) with a mean age of 43.4 years (range 18–80); 33.3 % reported ever using prefilled syringes, although only 4.9 % reported use in the past 6 months. In multivariable analyses, PFSU was independently associated with ever having a rushed injection due to police presence [adjusted odds ratio (AOR) = 2.51, 95 % CI 1.66, 3.79], ever being in prison (AOR = 1.80, 95 % CI 1.23, 2.63), injecting most often in public versus private places in the past 6 months (AOR = 1.66, 95 % CI 1.11, 2.48), and injecting drugs in Mexico (AOR = 1.70, 95 % CI 1.16, 2.49). Results indicate that a history of PFSU is common and associated with environmental factors that may also increase risk for adverse health outcomes. Studies are needed to better understand PFSU in order to develop interventions to prevent adverse outcomes associated with their use.

Published
2015

16. Feasibility of tuberculosis treatment monitoring by video directly observed therapy: a binational pilot study

Author

Garfein, RS, Collins, K, Muñoz, F, Moser, K, Cerecer-Callu, P, Raab, F, Rios, P, Flick, A, Zúñiga, ML, Cuevas-Mota, J, Liang, K, Rangel, G, Burgos, JL, Rodwell, TC, and Patrick, K

Subjects
Health Services and Systems, Biomedical and Clinical Sciences, Health Sciences, Infectious Diseases, Emerging Infectious Diseases, Orphan Drug, Tuberculosis, Clinical Research, Clinical Trials and Supportive Activities, Rare Diseases, Behavioral and Social Science, Good Health and Well Being, Adolescent, Adult, Aged, Aged, 80 and over, Antitubercular Agents, California, Cell Phone, Cost-Benefit Analysis, Directly Observed Therapy, Feasibility Studies, Female, Humans, Male, Medication Adherence, Mexico, Middle Aged, Pilot Projects, Telemedicine, Video Recording, Young Adult, US-Mexico border, drug resistance, medication adherence, DOT, cellular phone, mHealth, Cardiorespiratory Medicine and Haematology, Microbiology, Cardiovascular medicine and haematology, Clinical sciences, Epidemiology
Abstract

BackgroundAlthough directly observed therapy (DOT) is recommended worldwide for monitoring anti-tuberculosis treatment, transportation and personnel requirements limit its use.ObjectiveTo evaluate the feasibility and acceptability of 'video DOT' (VDOT), which allows patients to record and transmit medication ingestion via videos watched remotely by health care providers to document adherence.MethodsWe conducted a single-arm trial among tuberculosis (TB) patients in San Diego, California, USA, (n = 43) and Tijuana, Mexico (n = 9) to represent high- and low-resource settings. Pre-/post-treatment interviews assessed participant characteristics and experiences. Adherence was defined as the proportion of observed doses to expected doses.ResultsThe mean age was 37 years (range 18-86), 50% were male, and 88% were non-Caucasian. The mean duration of VDOT use was 5.5 months (range 1-11). Adherence was similar in San Diego (93%) and Tijuana (96%). Compared to time on in-person DOT, 92% preferred VDOT, 81% thought VDOT was more confidential, 89% never/rarely had problems recording videos, and 100% would recommend VDOT to others. Seven (13%) participants were returned to in-person DOT and six (12%) additional participants had their phones lost, broken or stolen.ConclusionsVDOT was feasible and acceptable, with high adherence in both high- and low-resource settings. Efficacy and cost-effectiveness studies are needed.

Published
2015

22. Using Scipion for stream image processing at Cryo-EM facilities

Author

Gómez-Blanco, J., de la Rosa-Trevín, J.M., Marabini, R., del Cano, L., Jiménez, A., Martínez, M., Melero, R., Majtner, T., Maluenda, D., Mota, J., Rancel, Y., Ramírez-Aportela, E, Vilas, J.L., Carroni, M., Fleischmann, S., Lindahl, E., Ashton, A.W., Basham, M., Clare, D.K., Savage, K., Siebert, C.A., Sharov, G.G., Sorzano, C.O.S., Conesa, P., and Carazo, J.M.

Published
2018
Full Text
View/download PDF

36. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants

Author

Zhou, B, Lu, Y, Hajifathalian, K, Bentham, J, Di Cesare, M, Danaei, G, Bixby, H, Cowan, MJ, Ali, MK, Taddei, C, Lo, WC, Reis-Santos, B, Stevens, GA, Riley, LM, Miranda, JJ, Bjerregaard, P, Rivera, JA, Fouad, HM, Ma, G, Mbanya, JC, McGarvey, ST, Mohan, V, Onat, A, Pilav, A, Ramachandran, A, Romdhane, HB, Paciorek, CJ, Bennett, JE, Ezzati, M, Abdeen, ZA, Abdul Kadir, K, Abu-Rmeileh, NM, Acosta-Cazares, B, Adams, R, Aekplakorn, W, Aguilar-Salinas, CA, Agyemang, C, Ahmadvand, A, Al-Othman, AR, Alkerwi, A, Amouyel, P, Amuzu, A, Andersen, LB, Anderssen, SA, Anjana, RM, Aounallah-Skhiri, H, Aris, T, Arlappa, N, Arveiler, D, Assah, FK, Avdicová, M, Azizi, F, Balakrishna, N, Bandosz, P, Barbagallo, CM, Barceló, A, Batieha, AM, Baur, LA, Benet, M, Bernabe-Ortiz, A, Bharadwaj, S, Bhargava, SK, Bi, Y, Bjertness, E, Bjertness, MB, Björkelund, C, Blokstra, A, Bo, S, Boehm, BO, Boissonnet, CP, Bovet, P, Brajkovich, I, Breckenkamp, J, Brenner, H, Brewster, LM, Brian, GR, Bruno, G, Bugge, A, Cabrera de León, A, Can, G, Cândido, AP, Capuano, V, Carlsson, AC, Carvalho, MJ, Casanueva, FF, Casas, JP, Caserta, CA, Castetbon, K, Chamukuttan, S, Chaturvedi, N, Chen, CJ, Chen, F, Chen, S, Cheng, CY, Chetrit, A, Chiou, ST, Cho, Y, Chudek, J, Cifkova, R, Claessens, F, Concin, H, Cooper, C, Cooper, R, Costanzo, S, Cottel, D, Cowell, C, Crujeiras, AB, D'Arrigo, G, Dallongeville, J, Dankner, R, Dauchet, L, de Gaetano, G, De Henauw, S, Deepa, M, Dehghan, A, Deschamps, V, Dhana, K, Di Castelnuovo, AF, Djalalinia, S, Doua, K, Drygas, W, Du, Y, Dzerve, V, Egbagbe, EE, Eggertsen, R, El Ati, J, Elosua, R, Erasmus, RT, Erem, C, Ergor, G, Eriksen, L, Escobedo-de la Peña, J, Fall, CH, Farzadfar, F, Felix-Redondo, FJ, Ferguson, TS, Fernández-Bergés, D, Ferrari, M, Ferreccio, C, Feskens, EJ, Finn, JD, Föger, B, Foo, LH, Forslund, AS, Francis, DK, Franco Mdo, C, Franco, OH, Frontera, G, Furusawa, T, Gaciong, Z, Garnett, SP, Gaspoz, JM, Gasull, M, Gates, L, Geleijnse, JM, Ghasemian, A, Ghimire, A, Giampaoli, S, Gianfagna, F, Giovannelli, J, Giwercman, A, Gross, MG, González Rivas, JP, Gorbea, MB, Gottrand, F, Grafnetter, D, Grodzicki, T, Grøntved, A, Gruden, G, Gu, D, Guan, OP, Guerrero, R, Guessous, I, Guimaraes, AL, Gutierrez, L, Hambleton, IR, Hardy, R, Hari Kumar, R, Hata, J, He, J, Heidemann, C, Herrala, S, Hihtaniemi, IT, Ho, SY, Ho, SC, Hofman, A, Hormiga, CM, Horta, BL, Houti, L, Howitt, C, Htay, TT, Htet, AS, Htike, MM, Hu, Y, Hussieni, AS, Huybrechts, I, Hwalla, N, Iacoviello, L, Iannone, AG, Ibrahim, MM, Ikeda, N, Ikram, MA, Irazola, VE, Islam, M, Iwasaki, M, Jacobs, JM, Jafar, T, Jamil, KM, Jasienska, G, Jiang, CQ, Jonas, JB, Joshi, P, Kafatos, A, Kalter-Leibovici, O, Kasaeian, A, Katz, J, Kaur, P, Kavousi, M, Keinänen-Kiukaanniemi, S, Kelishadi, R, Kengne, AP, Kersting, M, Khader, YS, Khalili, D, Khang, YH, Kiechl, S, Kim, J, Kolsteren, P, Korrovits, P, Kratzer, W, Kromhout, D, Kujala, UM, Kula, K, Kyobutungi, C, Laatikainen, T, Lachat, C, Laid, Y, Lam, TH, Landrove, O, Lanska, V, Lappas, G, Laxmaiah, A, Leclercq, C, Lee, J, Lehtimäki, T, Lekhraj, R, León-Muñoz, LM, Li, Y, Lim, WY, Lima-Costa, MF, Lin, HH, Lin, X, Lissner, L, Lorbeer, R, Lozano, JE, Luksiene, D, Lundqvist, A, Lytsy, P, Machado-Coelho, GL, Machi, S, Maggi, S, Magliano, DJ, Makdisse, M, Mallikharjuna Rao, K, Manios, Y, Manzato, E, Margozzini, P, Marques-Vidal, P, Martorell, R, Masoodi, SR, Mathiesen, EB, Matsha, TE, McFarlane, SR, McLachlan, S, McNulty, BA, Mediene-Benchekor, S, Meirhaeghe, A, Menezes, AM, Merat, S, Meshram, II, Mi, J, Miquel, JF, Mohamed, MK, Mohammad, K, Mohammadifard, N, Mohd Yusoff, MF, Møller, NC, Molnár, D, Mondo, CK, Morejon, A, Moreno, LA, Morgan, K, Moschonis, G, Mossakowska, M, Mostafa, A, Mota, J, Motta, J, Mu, TT, Muiesan, ML, Müller-Nurasyid, M, Mursu, J, Nagel, G, Námešná, J, Nang, EE, NangThetia, VB, Navarrete-Muñoz, EM, Ndiaye, NC, Nenko, I, Nervi, F, Nguyen, ND, Nguyen, QN, Nieto-Martínez, RE, Ning, G, Ninomiya, T, Noale, M, Noto, D, Nsour, MA, Ochoa-Avilés, AM, Oh, K, Ordunez, P, Osmond, C, Otero, JA, Owusu-Dabo, E, Pahomova, E, Palmieri, L, Panda-Jonas, S, Panza, F, Parsaeian, M, Peixoto, SV, Pelletier, C, Peltonen, M, Peters, A, Peykari, N, Pham, ST, Pitakaka, F, Piwonska, A, Piwonski, J, Plans-Rubió, P, Porta, M, Portegies, ML, Poustchi, H, Pradeepa, R, Price, JF, Punab, M, Qasrawi, RF, Qorbani, M, Radisauskas, R, Rahman, M, Raitakari, O, Rao, SR, Ramke, J, Ramos, R, Rampal, S, Rathmann, W, Redon, J, Reganit, PF, Rigo, F, Robinson, SM, Robitaille, C, Rodríguez-Artalejo, F, Rodriguez-Perez Mdel, C, Rodríguez-Villamizar, LA, Rojas-Martinez, R, Ronkainen, K, Rosengren, A, Rubinstein, A, Rui, O, Ruiz-Betancourt, BS, Russo Horimoto, RV, Rutkowski, M, Sabanayagam, C, Sachdev, HS, Saidi, O, Sakarya, S, Salanave, B, Salonen, JT, Salvetti, M, Sánchez-Abanto, J, Santos, D, dos Santos, RN, Santos, R, Saramies, JL, Sardinha, LB, Sarrafzadegan, N, Saum, KU, Scazufca, M, Schargrodsky, H, Scheidt-Nave, C, Sein, AA, Sharma, SK, Shaw, JE, Shibuya, K, Shin, Y, Shiri, R, Siantar, R, Sibai, AM, Simon, M, Simons, J, Simons, LA, Sjostrom, M, Slowikowska-Hilczer, J, Slusarczyk, P, Smeeth, L, Snijder, MB, So, HK, Sobngwi, E, Söderberg, S, Solfrizzi, V, Sonestedt, E, Soumare, A, Staessen, JA, Stathopoulou, MG, Steene-Johannessen, J, Stehle, P, Stein, AD, Stessman, J, Stöckl, D, Stokwiszewski, J, Stronks, K, Strufaldi, MW, Sun, CA, Sundström, J, Sung, YT, Suriyawongpaisal, P, Sy, RG, Tai, ES, Tamosiunas, A, Tang, L, Tarawneh, M, Tarqui-Mamani, CB, Taylor, A, Theobald, H, Thijs, L, Thuesen, BH, Tolonen, HK, Tolstrup, JS, Topbas, M, Torrent, M, Traissac, P, Trinh, OT, Tulloch-Reid, MK, Tuomainen, TP, Turley, ML, Tzourio, C, Ueda, P, Ukoli, FA, Ulmer, H, Uusitalo, HM, Valdivia, G, Valvi, D, van Rossem, L, van Valkengoed, IG, Vanderschueren, D, Vanuzzo, D, Vega, T, Velasquez-Melendez, G, Veronesi, G, Verschuren, WM, Verstraeten, R, Viet, L, Vioque, J, Virtanen, JK, Visvikis-Siest, S, Viswanathan, B, Vollenweider, P, Voutilainen, S, Vrijheid, M, Wade, AN, Wagner, A, Walton, J, Wan Mohamud, WN, Wang, F, Wang, MD, Wang, Q, Wang, YX, Wannamethee, SG, Weerasekera, D, Whincup, PH, Widhalm, K, Wiecek, A, Wijga, AH, Wilks, RJ, Willeit, J, Wilsgaard, T, Wojtyniak, B, Wong, TY, Woo, J, Woodward, M, Wu, FC, Wu, SL, Xu, H, Yan, W, Yang, X, Ye, X, Yoshihara, A, Younger-Coleman, NO, Zambon, S, Zargar, AH, Zdrojewski, T, Zhao, W, Zheng, Y, and Zuñiga Cisneros, J

Published
2016
Full Text
View/download PDF

39. Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331 288 participants

Author

Danaei, G, Fahimi, S, Lu, Y, Zhou, B, Hajifathalian, K, Di Cesare, M, Lo, WC, Reis-Santos, B, Cowan, MJ, Shaw, JE, Bentham, J, Lin, JK, Bixby, H, Magliano, D, Bovet, P, Miranda, JJ, Khang, YH, Stevens, GA, Riley, LM, Ali, MK, Ezzati, M, Abdeen, ZA, Kadir, KA, Abu-Rmeileh, M, Acosta-Cazares, B, Aekplakorn, W, Aguilar-Salinas, CA, Ahmadvand, A, Al Nsour, M, Alkerwi, A, Amouyel, P, Andersen, LB, Anderssen, SA, Andrade, DS, Anjana, RM, Aounallah-Skhiri, H, Aris, T, Arlappa, N, Arveiler, D, Assah, FK, Avdicová, M, Balakrishna, N, Bandosz, P, Barbagallo, CM, Barceló, A, Batieha, AM, Baur, LA, Ben Romdhane, H, Bernabe-Ortiz, A, Bhargava, SK, Bi, Y, Bjerregaard, P, Björkelund, C, Blake, M, Blokstra, A, Bo, S, Boehm, BO, Boissonnet, CP, Brajkovich, I, Breckenkamp, J, Brewster, LM, Brian, GR, Bruno, G, Bugge, A, Cabrera de León, A, Can, G, Cândido, AP, Capuano, V, Carvalho, MJ, Casanueva, FF, Caserta, CA, Castetbon, K, Chamukuttan, S, Chaturvedi, N, Chen, CJ, Chen, F, Chen, S, Cheng, CY, Chetrit, A, Chiou, ST, Cho, Y, Chudek, J, Cifkova, R, Claessens, F, Concin, H, Cooper, C, Cooper, R, Costanzo, S, Cottel, D, Cowell, C, Crujeiras, AB, D'Arrigo, G, Dallongeville, J, Dankner, R, Dauchet, L, de Gaetano, G, De Henauw, S, Deepa, M, Dehghan, A, Dhana, K, Di Castelnuovo, AF, Djalalinia, S, Doua, K, Drygas, W, Du, Y, Egbagbe, EE, Eggertsen, R, El Ati, J, Elosua, R, Erasmus, RT, Erem, C, Ergor, G, Eriksen, L, Escobedo-de la Peña, J, Fall, CH, Farzadfar, F, Felix-Redondo, FJ, Ferguson, TS, Fernández-Bergés, D, Ferrari, M, Ferreccio, C, Finn, JD, Föger, B, Foo, LH, Fouad, HM, Francis, DK, Franco Mdo, C, Frontera, G, Furusawa, T, Gaciong, Z, Galbarczyk, A, Garnett, SP, Gaspoz, JM, Gasull, M, Gates, L, Geleijnse, JM, Ghasemain, A, Giampaoli, S, Gianfagna, F, Giovannelli, J, Gonzalez Gross, M, González Rivas, JP, Gorbea, MB, Gottrand, F, Grant, JF, Grodzicki, T, Grøntved, A, Gruden, G, Gu, D, Guan, OP, Guerrero, R, Guessous, I, Guimaraes, AL, Gutierrez, L, Hardy, R, Hari Kumar, R, Heidemann, C, Hihtaniemi, IT, Ho, SY, Ho, SC, Hofman, A, Horimoto, AR, Hormiga, CM, Horta, BL, Houti, L, Hussieni, AS, Huybrechts, I, Hwalla, N, Iacoviello, L, Iannone, AG, Ibrahim, MM, Ikeda, N, Ikram, MA, Irazola, VE, Islam, M, Iwasaki, M, Jacobs, JM, Jafar, T, Jasienska, G, Jiang, CQ, Jonas, JB, Joshi, P, Kafatos, A, Kalter-Leibovici, O, Kasaeian, A, Katz, J, Kaur, P, Kavousi, M, Kelishadi, R, Kengne, AP, Kersting, M, Khader, YS, Kiechl, S, Kim, J, Kiyohara, Y, Kolsteren, P, Korrovits, P, Koskinen, S, Kratzer, W, Kromhout, D, Kula, K, Kurjata, P, Kyobutungi, C, Lachat, C, Laid, Y, Lam, TH, Lanska, V, Lappas, G, Laxmaiah, A, Leclercq, C, Lee, J, Lehtimäki, T, Lekhraj, R, León-Muñoz, LM, Li, Y, Lim, WY, Lima-Costa, MF, Lin, HH, Lin, X, Lissner, L, Lorbeer, R, Lozano, JE, Lundqvist, A, Lytsy, P, Ma, G, Machado-Coelho, GL, Machi, S, Maggi, S, Makdisse, M, Mallikharjuna v, K, Manios, Y, Manzato, E, Margozzini, P, Marques-Vidal, P, Martorell, R, Masoodi, SR, Matsha, TE, Mbanya, JC, McFarlane, SR, McGarvey, ST, McLachlan, S, McNulty, BA, Mediene-Benchekor, S, Meirhaeghe, A, Menezes, AM, Merat, S, Meshram, II, Mi, J, Miquel, JF, Mohamed, MK, Mohammad, K, Mohan, V, Mohd Yusoff, MF, Møller, NC, Molnar, D, Mondo, CK, Moreno, LA, Morgan, K, Moschonis, G, Mossakowska, M, Mostafa, A, Mota, J, Muiesan, ML, Müller-Nurasyid, M, Mursu, J, Nagel, G, Námešná, J, Nang, EE, Nangia, VB, Navarrete-Muñoz, EM, Ndiaye, NC, Nervi, F, Nguyen, ND, Nieto-Martínez, RE, Alvarado, L, Ning, G, Ninomiya, T, Noale, M, Noto, D, Ochoa-Avilés, M, Oh, K, Onat, A, Osmond, C, Otero, JA, Palmieri, L, Panda-Jonas, S, Panza, F, Parsaeian, M, Peixoto, SV, Pereira, AC, Peters, A, Peykari, N, Pilav, A, Pitakaka, F, Piwonska, A, Piwonski, J, Plans-Rubió, P, Porta, M, Portegies, ML, Poustchi, H, Pradeepa, R, Price, JF, Punab, M, Qasrawi, RF, Qorbani, M, Raitakari, O, Ramachandra Rao, S, Ramachandran, A, Ramos, R, Rampal, S, Rathmann, W, Redon, J, Reganit, PF, Rigo, F, Robinson, SM, Robitaille, C, Rodríguez, LA, Rodríguez-Artalejo, F, del Cristo Rodriguez-Perez, M, Rojas-Martinez, R, Romaguera, D, Rosengren, A, Rubinstein, A, Rui, O, Ruiz-Betancourt, BS, Rutkowski, M, Sabanayagam, C, Sachdev, HS, Saidi, O, Sakarya, S, Salanave, B, Salonen, JT, Salvetti, M, Sánchez-Abanto, J, Santos, RN, Santos, R, Sardinha, LB, Scazufca, M, Schargrodsky, H, Scheidt-Nave, C, Shibuya, K, Shin, Y, Shiri, R, Siantar, R, Sibai, AM, Simon, M, Simons, J, Simons, LA, Sjostrom, M, Slowikowska-Hilczer, J, Slusarczyk, P, Smeeth, L, Snijder, MB, Solfrizzi, V, Sonestedt, E, Soumare, A, Staessen, JA, Steene-Johannessen, J, Stehle, P, Stein, AD, Stessman, J, Stöckl, D, Stokwiszewski, J, Strufaldi, MW, Sun, CA, Sundström, J, Suriyawongpaisal, P, Sy, RG, Tai, ES, Tarawneh, M, Tarqui-Mamani, CB, Thijs, L, Tolstrup, JS, Topbas, M, Torrent, M, Traissac, P, Trinh, OT, Tulloch-Reid, MK, Tuomainen, TP, Turley, ML, Tzourio, C, Ueda, P, Ukoli, FM, Ulmer, H, Valdivia, G, van Valkengoed, IG, Vanderschueren, D, Vanuzzo, D, Vega, T, Velasquez-Melendez, G, Veronesi, G, Verschuren, M, Vioque, J, Virtanen, J, Visvikis-Siest, S, Viswanathan, B, Vollenweider, P, Voutilainen, S, Wade, AN, Wagner, A, Walton, J, Mohamud, WN, Wang, MD, Wang, YX, Wannamethee, SG, Weerasekera, D, Whincup, PH, Widhalm, K, Wiecek, A, Wilks, RJ, Willeit, J, Wojtyniak, B, Wong, TY, Woo, J, Woodward, M, Wu, AG, Wu, FC, Wu, SL, Xu, H, Yang, X, Ye, X, Yoshihara, A, Younger-Coleman, NO, Zambon, S, Zargar, AH, Zdrojewski, T, Zhao, W, and Zheng, Y

Published
2015
Full Text
View/download PDF

48. ΒN-Alkanoyl-5-Hydroxytryptamines (Cn-5HTs) in Coffee: A Review.

Author

Brand, A. L. M., Lima, F. A., Tinoco, N. A. B., Mota, J. C., Moreira, I. G. S., Novaes, F. J. M., Garrett, R., Giorno, T. B. S., Fernandes, P. D., and Rezende, C. M.

Subjects
COFFEE beans, COFFEE brewing, COFFEE, COFFEE drinks, COFFEE drinking, SEROTONIN
Abstract

ΒN-alkanoyl-5-hydroxytryptamines (Cn-5HTs) are serotonin amides that contain saturated or unsaturated alkyl long chains. They can be found in the waxy layer that covers the coffee bean and are also present in the coffee brew, one of the most popular beverages in the world. These substances exhibit relevant biological activities, such as antinociceptive and neuroprotective, despite being responsible for the stomach irritation observed in some individuals after drinking coffee. This review depicts the extraction and quantification of Cn-5HTs in green and roasted coffee beans, and coffee brew. Additionally, it illustrates the biological activities, synthetic strategies, and products formed during the roasting of the coffee bean, regarding the serotonin amides. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. Creating access to SARS-CoV-2 screening and testing through community-based COVID-19 case-finding, observations from cross-sectional studies in Lesotho and Zambia.

Author

Klinkenberg, Eveline, Katende, Bulemba, Ruperez, Maria, Bresser, Moniek, Kangololo, Bxyn, Bwalya, Justin, Erhardt, Rahel M., Schaap, Ab, Kasese, Nkatya, Gatchie, Thomas, Floyd, Sian, 'Mota, 'Mota J., Ayles, Helen, Shanaube, Kwame, and Reither, Klaus

Subjects
MEDICAL personnel, COVID-19 testing, COMMUNITY health workers, COVID-19, SMELL disorders, CROSS-sectional method
Abstract

Background: The health impact of the COVID-19 pandemic largely depends on the ability of the healthcare systems to develop effective and adaptable preparedness and mitigation strategies. A collaborative initiative (BRCCH-EDCTP COVID-19 Initiative) was set up between Lesotho and Zambia early on in the pandemic, to jointly conduct a project to investigate creating access to SARS-CoV-2 screening and testing through community-based COVID-19 case-finding. Methods: Two different community case-finding strategies were deployed. In Lesotho, an approach was implemented whereby a community (village) health worker screened community members at their home or during community gatherings for COVID-19 signs and symptoms. All community members who screened positive were then offered SARS-CoV-2 testing. In Zambia, so-called community hubs, staffed by community health care workers, were set up at different locations in the community for people to walk in and get tested for SARS-CoV-2. Hubs changed location from week-to-week and targeted transmission hotspots. All persons visiting the hubs were offered testing for SARS-CoV-2 irrespective of self-reported signs and symptoms of COVID-19 though information was collected on occurrence of these. Testing in both approaches was done using SARS-CoV-2 rapid antigen tests. Results: Setting up testing in the community setting was feasible in both countries. In Lesotho in the village health worker approach, over a period of 46 weeks, 7221 persons were screened, and 49 (11.4%) SARS-COV-2 cases identified among 428 COVID-19 screen positive participants. In the community hubs among 3150 people tested, 166 (5.3%) SARS-CoV-2 cases were identified in a period of 26 weeks. From the community hubs approach, where all seen were offered COVID-19 testing it was learned that people screening positive for COVID-19 signs and symptoms were more likely to test SARS-COV-2 positive, especially those reporting classic COVID-19 symptoms like loss of sense/smell for a short period of time (1–3 days). Conclusions: In conclusion, in this project we learned that implementing COVID-19 screening and testing by lay health workers in the community is possible. Characteristics of the population screened, tested, and identified to have SARS-CoV-2 are described to help guide development of future testing strategies. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results